Ascentage Pharma Group Inc.
Clinical trials sponsored by Ascentage Pharma Group Inc., explained in plain language.
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests an oral drug called APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to find a safe dose and check for side effects. About 74 participants will take the drug by mouth…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 26, 2026 09:52 UTC
-
New hope for drug-resistant lung cancer? early trial combines two targeted therapies
Disease control OngoingThis early-stage study tests a new drug (APG-1252) combined with a standard targeted therapy (osimertinib) in people with a specific type of advanced lung cancer (EGFR-positive NSCLC) whose cancer has stopped responding to previous treatments. The main goals are to find the safes…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC